Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial
2023 · The Lancet Regional Health - Western Pacific · 9 citations
https://doi.org/10.1016/j.lanwpc.2023.100953